Genmab — Juli 2023
-
Johnson & Johnson Poised For A Muted Q2? https://www.proinvestor.com/investornyt/1015967/johnson-amp-johnson-poised-for-a-muted-q2
-
Antengene : Xpovio Approved In Hong Kong For Relapsed And/or Refractory Multiple Myeloma Treatment https://www.proinvestor.com/investornyt/1015963/antengene-xpovio-approved-in-hong-kong-for-relapsed-and-or-refractory-multiple-myeloma-treatment
-
Caribou Biosciences has reported new follow-up data from the dose-escalation portion of its ongoing Phase I ANTLER study, which is evaluating the allogeneic anti-CD19 CAR-T therapy CB-010 in 16 patients with relapsed or refractory B-cell non-Hodgkin's lymphoma (NHL) https://firstwordpharma.com/story/5761039?aid=5761039
-
Both epcoritamab and talquetamab on the CHMP agenda this week https://www.ema.europa.eu/en/documents/agenda/agenda-chmp-meeting-17-20-july-2023_en.pdf
-
Daratumumab in first-line treatment of patients with light chain amyloidosis and Mayo stage IIIb improves treatment response and overall survival https://www.researchgate.net/publication/372343645_Daratumumab_in_first-line_treatment_of_patients_with_light_chain_amyloidosis_and_Mayo_stage_IIIb_improves_treatment_response_and_overall_survival
-
https://www.prnewswire.com/news-releases/treatment-with-rybrevant-amivantamab-vmjw-plus-chemotherapy-resulted-in-statistically-significant-and-clinically-meaningful-improvement-in-progression-free-survival-in-patients-with-newly-diagnosed-egfr-exon-20-insertion-mutati-301878443.html?tc=eml_cleartime Treatment with RYBREVANT
(amivantamab-vmjw) Plus Chemotherapy Resulted in Statistically Significant and Clinically Meaningful Improvement in Progression-Free Survival in Patients with Newly Diagnose -
Nå...nu ser det da ud til at retningen er UP:-)
-
Ja og snakken om kurs 2450 forstummede. Saxo kører med et muligt bull signal omkring 2950 over 50 dage, hvis wedgen bryde op
-
Genmab (+2,3%, 2686) parternen Novartis øgede i andet kvartal salget af Kesimpta til 489 mio. dollar. Det svarer til en stigning på 105 pct. sammenlignet med salget i samme kvartal sidste år. Kesimpta til behandling af multipel sklerose er baseret på Genmabs virkemiddel Ofatumumab, og Genmab modtager 10 pct. af salget i royalties. Kilde: Landbobanken Børsnyt
-
Schweizisk Genmab-partner opjusterer efter overbevisende kvartal https://www.proinvestor.com/investornyt/1016615/schweizisk-genmab-partner-opjusterer-efter-overbevisende-kvartal
-
Novartis Q2 2023 Results
Investor
presentation https://www.novartis.com/sites/novartis_com/files/q2-2023-investor-presentation.pdf -
Q1: $386 mln, Q2: $489 mln og $873 mln for H123. Vi er vel over BB nu
https://www.novartis.com/sites/novartis_com/files/q2-2023-media-release-en.pdf side 5
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind